Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJean‐Jacques Grob, Axel Hauschild, Salvador Martín‐Algarra et al.|Annals of Oncology|2014Cited by 55